Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Group

Basit Öğe Kaydı
dc.authoridkose, fatih/0000-0002-0156-5973
dc.authoridBesen, Ali Ayberk/0000-0002-7862-0192
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridTanriverdi, Ozgur/0000-0002-0598-7284
dc.authoridOzyilkan, Ozgur/0000-0001-8825-4918
dc.authoridSumbul, Ahmet T/0000-0002-5573-906X
dc.authorwosidABALI, Hüseyin/D-7660-2016
dc.authorwosidkose, fatih/G-4827-2016
dc.authorwosidBesen, Ali Ayberk/AAD-6910-2021
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidTanriverdi, Ozgur/M-2172-2015
dc.authorwosidOzyilkan, Ozgur/AAD-2817-2021
dc.authorwosidSumbul, Ahmet T/D-4793-2014
dc.contributor.authorSedef, Ali Murat
dc.contributor.authorKose, Fatih
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorHacioglu, Bekir
dc.contributor.authorGunaldi, Meral
dc.contributor.authorNayir, Erdinc
dc.date.accessioned2024-06-12T11:02:30Z
dc.date.available2024-06-12T11:02:30Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose: Advanced gastric cancer has a dismal prognosis. Platin/5-fluorouracil (PF) combination chemotherapy is the main treatment modality for metastatic gastric cancer patients. Third drug addition to PF is a controversial issue. The aim of this study was to evaluate the predictive role of tumor localization and histopathology on choosing three- or two-drug combination regimens. Methods: This study was designed as a hospital-based retrospective observational case-series study. A total of 516 patients with advanced gastric cancer has been treated at eight different oncology centers in Turkey between 2006 and 2016. Laboratory results and demographic data were collected and analyzed. Results: The median patient age was 59 years (range 25-85). Proximal intestinal and distal intestinal cancers were found in 357 (69.2 %) and 159 (30.8 %) patients, respectively. 5-fluorouracil (5FU) and cisplatin (PF) and cisplatin+5FU+docetaxel (PFtax, also known as DCF) were administered to 240 (46.5%) and 276 (53.5%) patients, respectively. Median progression free survival (PFS) was 5.0 (95% CI 4.21-5.29) and 8 months (95% CI 7.22-8.77)for PF and PFtax groups, respectively (p<0.01). When tumor localization was used as stratum in PFS survival, PFtax produced significantly higher PFS rates only in distal intestinal type gastric cancer compared to PF (p <0.01). Median overall survival (OS) was 12 (95% CI 9.8-14.2) and 16 months (95% CI 13.6-18.4)for the PF and PFtax groups, respectively (p=0.01). When tumor localization was used as stratum in OS, PFtax showed significantly higher OS rates only in the distal intestinal type gastric cancer compared to PF (p=0.01). Conclusion: Pathology and tumor location in gastric cancer may affect the outcome. Addition of taxanes as a third drug may significantly increase PFS and OS rates only in distal intestinal type gastric cancer but not in patients with proximal type gastric cancer.en_US
dc.identifier.endpage655en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue2en_US
dc.identifier.pmid31128019en_US
dc.identifier.scopus2-s2.0-85064661823en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage650en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21294
dc.identifier.volume24en_US
dc.identifier.wosWOS:000464461100035en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastric Canceren_US
dc.subjectTumor Locationen_US
dc.subjectPathologyen_US
dc.subjectOutcomeen_US
dc.subjectIn-Situ Hybridizationen_US
dc.subjectPhase-Iiien_US
dc.subjectImmunohistochemistryen_US
dc.subjectAdenocarcinomaen_US
dc.subjectFluorouracilen_US
dc.subjectCisplatinen_US
dc.subjectDocetaxelen_US
dc.subjectResectionen_US
dc.titleAddition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximal ones: A multicenter retrospective study of Turkish Oncology Groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu